Tactile Systems (TCMD) Stock Forecast & Price Target

Tactile Systems Tech is experiencing positive growth potential from increased sales and productivity, as well as seeking FDA approval for expanded use of their core product. The company is making strategic efforts to improve patient access and diagnosis, while also expanding their product line with the acquisition of LymphaTech. The projected revenue and adjusted EBITDA for FY26 reflects their strong financial growth potential, although competition and potential barriers to market adoption may pose risks.

Tactile Systems Tech is facing several challenges with their channel dynamics, including slower-than-expected uptake within commercial channels, limitations on sales force leverage, and competition with other devices like Airway Clearance. In addition, varying doctor opinions on the effectiveness of pneumatic compression as a standalone treatment could also hinder the company's growth. Although they have shown solid financials with consistent growth, there are risks such as slower rep hiring and changes in Medicare prior authorization requirements that may impact their ability to achieve their projected revenues.